Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ANDREW PEDINOFF

Allopathic & Osteopathic Physicians Allergy & Immunology

NPI
1033116801
CMS profile
364149
Location
SKILLMAN, NJ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$2,610.81

21 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $2,337.50 1
Food and Beverage $273.31 20

By paying entity

PY2021 · entire year · sorted by reported total

Page 1 of 1; records 1–21 of 21 matching records. This page contains 21 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ANDREW PEDINOFF

NPI 1033116801 · CMS profile ID 364149

Allopathic & Osteopathic Physicians / Allergy & Immunology

SKILLMAN, NJ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–21 of 21 matching records. This page contains 21 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1033116801?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ANDREW PEDINOFF, NPI 1033116801, CMS profile ID 364149. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–21 of 21 matching records. This page contains 21 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1033116801?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). ANDREW PEDINOFF, NPI 1033116801, CMS profile ID 364149. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–21 of 21 matching records. This page contains 21 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1033116801?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
ANDREW PEDINOFF, NPI 1033116801, CMS profile ID 364149, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–21 of 21 matching records. This page contains 21 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1033116801?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

21 matching records · $2,610.81 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 21 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–21 of 21.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Regeneron Healthcare Solutions, Inc. $14.3012/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809612971 CMS
Covis Pharma GmBH $14.8812/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 847687431 CMS
Teva Pharmaceuticals USA, Inc. $13.6810/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839673583 CMS
Merck Sharp & Dohme Corporation $11.3810/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848536879 CMS
Covis Pharma GmBH $15.3010/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 844396763 CMS
Covis Pharma GmBH $15.3010/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 847687427 CMS
Pharming Healthcare, Inc. $12.0710/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820560129 CMS
AstraZeneca Pharmaceuticals LP $14.9909/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829616507 CMS
AstraZeneca Pharmaceuticals LP $11.3709/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830020951 CMS
Phadia US Inc. $13.4909/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 770178172 CMS
kaleo, Inc. $14.0909/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832125253 CMS
AstraZeneca Pharmaceuticals LP $11.4609/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829523589 CMS
AstraZeneca Pharmaceuticals LP $11.5507/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829874629 CMS
Optinose US, Inc. $13.2207/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851670791 CMS
AstraZeneca Pharmaceuticals LP $14.9907/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829937615 CMS
GlaxoSmithKline, LLC. $14.8906/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802641855 CMS
AstraZeneca Pharmaceuticals LP $14.9906/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829607709 CMS
Novartis Pharmaceuticals Corporation $2,337.5006/01/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813156261 CMS
GlaxoSmithKline, LLC. $14.7205/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802233989 CMS
kaleo, Inc. $14.4103/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832125251 CMS
GlaxoSmithKline, LLC. $12.2303/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802217565 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2020 $14.87 1
PY2021 $2,610.81 21
PY2022 $282.79 24
PY2023 $186.57 18

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2020, 2021, 2022, 2023
Source files and profile matching
Source files
Dataset page · Bulk file · PY2020 , PY2021 , PY2022 , PY2023
Generated from
OP_DTL_GNRL_PGYR2023_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2024 Principal investigator $12,078.66 3
PY2023 Principal investigator $155,562.82 28
PY2022 Principal investigator $467,597.19 23
PY2021 Principal investigator $355,310.51 36
PY2020 Principal investigator $554,325.08 51
PY2019 Principal investigator $722,989.71 74

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

74 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Allergan Inc. $15,784.52 12/31/2019 Non-covered Recipient Entity
PRINCETON CTR FOR CLINICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670122746
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,309.56 12/31/2019 Non-covered Recipient Entity
Princeton Center For Clinical
A Randomized Double-Blind Parallel Group Multi-Center 24-Week Study Comparing the Efficacy and Safety of Three Doses of PT001 to Placebo and Open-label Spiriva Respimat in Subjects With Persistent Asthma No dispute reported 06/30/2026 684989029
Principal investigator 1 Hikma Pharmaceuticals USA $3,433.75 12/30/2019 Non-covered Recipient Entity
PRINCETON CENTER FOR CLINICAL RESEARCH
Fluticasone Salmeterol Powder, 100mcg50mcg Multicenter Clinical Endpoint Study No dispute reported 06/30/2026 641063593
Principal investigator 1 CIPLA USA INC. $183.71 12/26/2019 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
U-FS-MU-AS3120 No dispute reported 06/30/2026 694710711
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,251.00 12/19/2019 Non-covered Recipient Entity
Princeton Center for Clinical Research
A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma No dispute reported 06/30/2026 685023757
Principal investigator 1 Allergan Inc. $700.00 12/17/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670115479
Principal investigator 1 Allergan Inc. $5,597.40 12/13/2019 Non-covered Recipient Entity
PRINCETON CTR FOR CLINICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670110669
Principal investigator 1 Amphastar Pharmaceuticals, Inc. $75,206.00 12/13/2019 Non-covered Recipient Entity
Princeton Center for Clinical Research
Pharmacodynamic (PD) Bronchodilatation Bioequivalence (BE) Study of Albuterol Sulfate HFA MDI 90 mcg/inhalation in Asthma Patients No dispute reported 06/30/2026 655968297
Principal investigator 1 CIPLA USA INC. $62,004.85 11/27/2019 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
U-FS-MU-AS3120 No dispute reported 06/30/2026 694711993
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $16,713.00 11/18/2019 Non-covered Recipient Entity
Princeton Center for Clinical Research
A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma No dispute reported 06/30/2026 685023749
Principal investigator 1 Allergan Inc. $6,312.75 11/13/2019 Non-covered Recipient Entity
PRINCETON CTR FOR CLINICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670096825
Principal investigator 1 Allergan Inc. $86.00 11/12/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670095335
Principal investigator 1 Allergan Inc. $327.00 11/12/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670095511
Principal investigator 1 Novartis Pharmaceuticals Corporation $5,500.00 11/06/2019 Non-covered Recipient Entity
PRINCETON ALLERGY AND ASTHMA ASSOCIATES PA
A TWO TREATMENT EPOCH RANDOMIZED PLACEBO CONTROLLED MULTI CENTERED PARALLEL GROUP STUDY TO ASSESS THE SAFETY OF QAW039 WHEN ADDED TO EXISTING ASTHMA THERAPY IN PATIENTS WITH UNCONTROLLED SEVERE ASTHMA No dispute reported 06/30/2026 640724211
Principal investigator 1 CIPLA USA INC. $3,500.00 10/31/2019 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
U-FS-MU-AS3120 No dispute reported 06/30/2026 694712275
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $20,250.00 10/29/2019 Non-covered Recipient Entity
CRN Clinical Research Network
A Randomized, Multiple-Dose, Blinded, Placebo-Controlled, Parallel-Design, Multiple-Center, Clinical Study to Evaluate the Therapeutic Equivalence of Fluticasone Propionate and Salmeterol Inhalation Powder, 100 mcg/50 mcg to ADVAIR DISKUS 100/50 (Fluticasone Propionate/Salmeterol) Inhalation Powder, in Subjects With Asthma No dispute reported 06/30/2026 685017733
Principal investigator 1 CIPLA USA INC. $5.00 10/22/2019 Non-covered Recipient Entity
PRINCETON CENTER FOR CLINICAL RESEARCH
U-FS-MU-AS3120 No dispute reported 06/30/2026 694710323
Principal investigator 1 CIPLA USA INC. $10.00 10/22/2019 Non-covered Recipient Entity
PRINCETON CENTER FOR CLINICAL RESEARCH
U-FS-MU-AS3120 No dispute reported 06/30/2026 694715969
Principal investigator 1 Allergan Inc. $5,680.05 10/15/2019 Non-covered Recipient Entity
PRINCETON CTR FOR CLINICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670085693
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,424.00 10/11/2019 Non-covered Recipient Entity
Princeton Center for Clinical Research
A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma No dispute reported 06/30/2026 685023731
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $26,649.00 10/11/2019 Non-covered Recipient Entity
Princeton Center for Clinical Research
A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma No dispute reported 06/30/2026 685023739
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $17,050.00 10/09/2019 Non-covered Recipient Entity
CRN Clinical Research Network
A Randomized, Multiple-Dose, Blinded, Placebo-Controlled, Parallel-Design, Multiple-Center, Clinical Study to Evaluate the Therapeutic Equivalence of Fluticasone Propionate and Salmeterol Inhalation Powder, 100 mcg/50 mcg to ADVAIR DISKUS 100/50 (Fluticasone Propionate/Salmeterol) Inhalation Powder, in Subjects With Asthma No dispute reported 06/30/2026 685017727
Principal investigator 1 CIPLA USA INC. $24.00 10/01/2019 Non-covered Recipient Entity
PRINCETON CENTER FOR CLINICAL RESEARCH
U-FS-MU-AS3120 No dispute reported 06/30/2026 694716083
Principal investigator 1 CIPLA USA INC. $36.00 10/01/2019 Non-covered Recipient Entity
PRINCETON CENTER FOR CLINICAL RESEARCH
U-FS-MU-AS3120 No dispute reported 06/30/2026 694716089
Principal investigator 1 CIPLA USA INC. $633.30 09/28/2019 Non-covered Recipient Entity
PRINCETON CENTER FOR CLINICAL RESEARCH
U-FS-MU-AS3120 No dispute reported 06/30/2026 694710549
Principal investigator 1 CIPLA USA INC. $10.00 09/28/2019 Non-covered Recipient Entity
PRINCETON CENTER FOR CLINICAL RESEARCH
U-FS-MU-AS3120 No dispute reported 06/30/2026 694711345
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $24,840.00 09/19/2019 Non-covered Recipient Entity
CRN Clinical Research Network
A Randomized, Multiple-Dose, Blinded, Placebo-Controlled, Parallel-Design, Multiple-Center, Clinical Study to Evaluate the Therapeutic Equivalence of Fluticasone Propionate and Salmeterol Inhalation Powder, 100 mcg/50 mcg to ADVAIR DISKUS 100/50 (Fluticasone Propionate/Salmeterol) Inhalation Powder, in Subjects With Asthma No dispute reported 06/30/2026 685017203
Principal investigator 1 Allergan Inc. $8,644.05 09/18/2019 Non-covered Recipient Entity
PRINCETON CTR FOR CLINICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670076814
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $12,051.00 09/13/2019 Non-covered Recipient Entity
Princeton Center for Clinical Research
A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma No dispute reported 06/30/2026 685021178
Principal investigator 1 Allergan Inc. $86.00 09/05/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670072959
Principal investigator 1 Allergan Inc. $86.00 09/03/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670072305
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $14,238.00 08/29/2019 Non-covered Recipient Entity
Princeton Center for Clinical Research
A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma No dispute reported 06/30/2026 685021169
Principal investigator 1 CIPLA USA INC. $10,150.43 08/27/2019 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
U-FS-MU-AS3120 No dispute reported 06/30/2026 694714819
Principal investigator 1 Hikma Pharmaceuticals USA $8,205.00 08/27/2019 Non-covered Recipient Entity
PRINCETON CENTER FOR CLINICAL RESEARCH
Fluticasone Salmeterol Powder, 100mcg50mcg Multicenter Clinical Endpoint Study No dispute reported 06/30/2026 641063585
Principal investigator 1 Hikma Pharmaceuticals USA $472.00 08/27/2019 Non-covered Recipient Entity
PRINCETON CENTER FOR CLINICAL RESEARCH
Fluticasone Salmeterol Powder, 100mcg50mcg Multicenter Clinical Endpoint Study No dispute reported 06/30/2026 641063589
Principal investigator 1 CIPLA USA INC. $85.60 08/26/2019 Non-covered Recipient Entity
PRINCETON CENTER FOR CLINICAL RESEARCH
U-FS-MU-AS3120 No dispute reported 06/30/2026 694715089
Principal investigator 1 CIPLA USA INC. $36.80 08/26/2019 Non-covered Recipient Entity
PRINCETON CENTER FOR CLINICAL RESEARCH
U-FS-MU-AS3120 No dispute reported 06/30/2026 694715091
Principal investigator 1 CIPLA USA INC. $304.80 08/26/2019 Non-covered Recipient Entity
PRINCETON CENTER FOR CLINICAL RESEARCH
U-FS-MU-AS3120 No dispute reported 06/30/2026 694715095
Principal investigator 1 CIPLA USA INC. $46.00 08/26/2019 Non-covered Recipient Entity
PRINCETON CENTER FOR CLINICAL RESEARCH
U-FS-MU-AS3120 No dispute reported 06/30/2026 694715099
Principal investigator 1 Allergan Inc. $5,050.20 08/14/2019 Non-covered Recipient Entity
PRINCETON CTR FOR CLINICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670065495
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $27,270.00 08/01/2019 Non-covered Recipient Entity
CRN Clinical Research Network
A Randomized, Multiple-Dose, Blinded, Placebo-Controlled, Parallel-Design, Multiple-Center, Clinical Study to Evaluate the Therapeutic Equivalence of Fluticasone Propionate and Salmeterol Inhalation Powder, 100 mcg/50 mcg to ADVAIR DISKUS 100/50 (Fluticasone Propionate/Salmeterol) Inhalation Powder, in Subjects With Asthma No dispute reported 06/30/2026 685017197
Principal investigator 1 CIPLA USA INC. $16.80 07/23/2019 Non-covered Recipient Entity
PRINCETON CENTER FOR CLINICAL RESEARCH
U-FS-MU-AS3120 No dispute reported 06/30/2026 694714901
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $7,713.00 07/16/2019 Non-covered Recipient Entity
Princeton Center for Clinical Research
A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma No dispute reported 06/30/2026 685021159
Principal investigator 1 Allergan Inc. $14,406.75 07/15/2019 Non-covered Recipient Entity
PRINCETON CTR FOR CLINICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670057123
Principal investigator 1 CIPLA USA INC. $31,186.13 06/27/2019 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
U-FS-MU-AS3120 No dispute reported 06/30/2026 694714949
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $23,931.00 06/24/2019 Non-covered Recipient Entity
Princeton Center for Clinical Research
A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma No dispute reported 06/30/2026 685019205
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $6,480.00 06/11/2019 Non-covered Recipient Entity
CRN Clinical Research Network
A Randomized, Multiple-Dose, Blinded, Placebo-Controlled, Parallel-Design, Multiple-Center, Clinical Study to Evaluate the Therapeutic Equivalence of Fluticasone Propionate and Salmeterol Inhalation Powder, 100 mcg/50 mcg to ADVAIR DISKUS 100/50 (Fluticasone Propionate/Salmeterol) Inhalation Powder, in Subjects With Asthma No dispute reported 06/30/2026 685016835
Principal investigator 1 Allergan Inc. $7,575.30 05/28/2019 Non-covered Recipient Entity
PRINCETON CENTER FOR CLINICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670048169
Principal investigator 1 CIPLA USA INC. $10.00 05/15/2019 Non-covered Recipient Entity
PRINCETON CENTER FOR CLINICAL RESEARCH
U-FS-MU-AS3120 No dispute reported 06/30/2026 694714729
Principal investigator 1 CIPLA USA INC. $633.30 05/15/2019 Non-covered Recipient Entity
PRINCETON CENTER FOR CLINICAL RESEARCH
U-FS-MU-AS3120 No dispute reported 06/30/2026 694714733
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,500.00 05/14/2019 Non-covered Recipient Entity
Princeton Center for Clinical Research
A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma No dispute reported 06/30/2026 685019197
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $9,747.00 05/14/2019 Non-covered Recipient Entity
Princeton Center for Clinical Research
A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma No dispute reported 06/30/2026 685019201
Principal investigator 1 CIPLA USA INC. $39,799.43 05/02/2019 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
U-FS-MU-AS3120 No dispute reported 06/30/2026 694714247
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,500.00 05/02/2019 Non-covered Recipient Entity
Princeton Center for Clinical Research
A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma No dispute reported 06/30/2026 685019193
Principal investigator 1 Allergan Inc. $7,745.35 04/25/2019 Non-covered Recipient Entity
PRINCETON CENTER FOR CLINICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670041159
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $11,100.00 04/19/2019 Non-covered Recipient Entity
CRN Clinical Research Network
A Randomized, Multiple-Dose, Blinded, Placebo-Controlled, Parallel-Design, Multiple-Center, Clinical Study to Evaluate the Therapeutic Equivalence of Fluticasone Propionate and Salmeterol Inhalation Powder, 100 mcg/50 mcg to ADVAIR DISKUS 100/50 (Fluticasone Propionate/Salmeterol) Inhalation Powder, in Subjects With Asthma No dispute reported 06/30/2026 685016831
Principal investigator 1 SANOFI US SERVICES INC. $3,500.00 04/04/2019 Non-covered Recipient Entity
Princeton Center For Clinical Research
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 12-week Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety, and Tolerability of SAR440340 and the Coadministration of SAR440340 No dispute reported 06/30/2026 691552061
Principal investigator 1 Allergan Inc. $20,028.85 03/26/2019 Non-covered Recipient Entity
PRINCETON CENTER FOR CLINICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670033567
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,000.00 03/20/2019 Non-covered Recipient Entity
CRN Clinical Research Network
A Randomized, Multiple-Dose, Blinded, Placebo-Controlled, Parallel-Design, Multiple-Center, Clinical Study to Evaluate the Therapeutic Equivalence of Fluticasone Propionate and Salmeterol Inhalation Powder, 100 mcg/50 mcg to ADVAIR DISKUS 100/50 (Fluticasone Propionate/Salmeterol) Inhalation Powder, in Subjects With Asthma No dispute reported 06/30/2026 685016207
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $356.35 03/14/2019 Non-covered Recipient Entity
Princeton Center for Clinical Research
A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma No dispute reported 06/30/2026 685018403
Principal investigator 1 Hikma Pharmaceuticals USA $11,060.00 03/11/2019 Non-covered Recipient Entity
PRINCETON CENTER FOR CLINICAL RESEARCH
Fluticasone Salmeterol Powder, 100mcg50mcg Multicenter Clinical Endpoint Study No dispute reported 06/30/2026 641063303
Principal investigator 1 Allergan Inc. $1,262.55 02/28/2019 Non-covered Recipient Entity
PRINCETON CENTER FOR CLINICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670027850
Principal investigator 1 Allergan Inc. $6,500.00 02/21/2019 Non-covered Recipient Entity
PRINCETON CENTER FOR CLINICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670026537
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $18,600.00 02/07/2019 Non-covered Recipient Entity
CRN Clinical Research Network
A Randomized, Multiple-Dose, Blinded, Placebo-Controlled, Parallel-Design, Multiple-Center, Clinical Study to Evaluate the Therapeutic Equivalence of Fluticasone Propionate and Salmeterol Inhalation Powder, 100 mcg/50 mcg to ADVAIR DISKUS 100/50 (Fluticasone Propionate/Salmeterol) Inhalation Powder, in Subjects With Asthma No dispute reported 06/30/2026 685016201
Principal investigator 1 Allergan Inc. $5,460.60 02/05/2019 Non-covered Recipient Entity
PRINCETON CENTER FOR CLINICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670021595
Principal investigator 1 Allergan Inc. $500.00 01/22/2019 Non-covered Recipient Entity
PRINCETON CENTER FOR CLINICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670018759
Principal investigator 1 AstraZeneca Pharmaceuticals LP $6,011.99 01/22/2019 Non-covered Recipient Entity
Princeton Center For Clinical
A Randomized Double-Blind Parallel Group Multi-Center 24-Week Study Comparing the Efficacy and Safety of Three Doses of PT001 to Placebo and Open-label Spiriva Respimat in Subjects With Persistent Asthma No dispute reported 06/30/2026 684989025
Principal investigator 1 Hikma Pharmaceuticals USA $14,453.75 01/16/2019 Non-covered Recipient Entity
PRINCETON CENTER FOR CLINICAL RESEARCH
Fluticasone Salmeterol Powder, 100mcg50mcg Multicenter Clinical Endpoint Study No dispute reported 06/30/2026 641063301
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $317.29 01/16/2019 Non-covered Recipient Entity
CRN Clinical Research Network
A Randomized, Multiple-Dose, Blinded, Placebo-Controlled, Parallel-Design, Multiple-Center, Clinical Study to Evaluate the Therapeutic Equivalence of Fluticasone Propionate and Salmeterol Inhalation Powder, 100 mcg/50 mcg to ADVAIR DISKUS 100/50 (Fluticasone Propionate/Salmeterol) Inhalation Powder, in Subjects With Asthma No dispute reported 06/30/2026 685016199
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $307.84 01/15/2019 Non-covered Recipient Entity
CRN Clinical Research Network
A Randomized, Multiple-Dose, Blinded, Placebo-Controlled, Parallel-Design, Multiple-Center, Clinical Study to Evaluate the Therapeutic Equivalence of Fluticasone Propionate and Salmeterol Inhalation Powder, 100 mcg/50 mcg to ADVAIR DISKUS 100/50 (Fluticasone Propionate/Salmeterol) Inhalation Powder, in Subjects With Asthma No dispute reported 06/30/2026 685016195
Principal investigator 1 SANOFI US SERVICES INC. $3,967.00 01/09/2019 Non-covered Recipient Entity
Princeton Center For Clinical Research
Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Dupilumab in Patients With Asthma Who Participated in a Previous Dupilumab Asthma Clinical Study No dispute reported 06/30/2026 691543613
Principal investigator 1 Allergan Inc. $5,781.70 01/03/2019 Non-covered Recipient Entity
PRINCETON CENTER FOR CLINICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670014643
Principal investigator 1 Novartis Pharmaceuticals Corporation $58,425.16 01/01/2019 Non-covered Recipient Entity
PRINCETON CENTER FOR CLINICAL RESEARCH
A 12 WEEK MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF QAW039 WHEN ADDED TO STANDARD-OF-CARE ASTHMA THERAPY IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 640724219
Principal investigator 1 Novartis Pharmaceuticals Corporation $13,865.80 01/01/2019 Non-covered Recipient Entity
PRINCETON CENTER FOR CLINICAL RESEARCH
A MULTI CENTER RANDOMIZED 52 WEEKS TREATMENT DOUBLE BLIND TRIPLE DUMMY STUDY TO ASSESS THE EFFICACY AND SAFETY OF QMF149 COMPARED WITH MOMETASONE FUROATE AND SALMETEROL FLUTICASONE No dispute reported 06/30/2026 640724223